Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

Núñez, Estefanía; Fuster, Valentín; Gómez-Serrano, María; Valdivielso, José Manuel; Fernández-Alvira, Juan Miguel; Martínez-López, Diego; Rodrı́guez, José Manuel; Bonzón-Kulichenko, Elena; Alfayate, Alvaro; Bermúdez-López, Marcelino; Escolà‐Gil, Joan Carles; Fernández‐Friera, Leticia; Cerro-Pardo, Isabel; Mendiguren, José M.; Sánchez-Cabo, Fátima; Sanz, Javier; Ordovás, José M.; Blanco-Colio, Luis Miguel; García-Ruiz, José M.; Ibáñez, Borja; Lara‐Pezzi, Enrique; Fernández‐Ortíz, Antonio; Martı́n-Ventura, José Luis; Vázquez, Jesús

doi:10.1016/j.ebiom.2022.103874

Cited by 36 publications

(15 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discovery cohort containing 72 COVID-19 serum samples was analyzed by hypothesis free quantitative LC-MS using TMT multiplexed isobaric labeling and without depletion of the most abundant proteins to preserve the integrity of the serum proteome. Peptide fractionation was used instead ( Figure 1 ), an approach that improved peptide and protein yield and that has been demonstrated to be a reproducible method in previous studies [ 28 ]. Protein quantification was performed on the basis of the WSPP model using the SanXoT package, as we have done in previous serum proteomics studies [ 29 , 30 , 31 , 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), whose outbreak in 2019 led to an ongoing pandemic with devastating consequences for the global economy and human health. According to the World Health Organization, COVID-19 has affected more than 481 million people worldwide, with 6 million confirmed deaths. The joint efforts of the scientific community have undoubtedly increased the pace of production of COVID-19 vaccines, but there is still so much uncharted ground to cover regarding the mechanisms of SARS-CoV-2 infection, replication and host response. These issues can be approached by proteomics with unprecedented capacity paving the way for the development of more efficient strategies for patient care. In this study, we present a deep proteome analysis that has been performed on a cohort of 72 COVID-19 patients aiming to identify serum proteins assessing the dynamics of the disease at different age ranges. A panel of 53 proteins that participate in several functions such as acute-phase response and inflammation, blood coagulation, cell adhesion, complement cascade, endocytosis, immune response, oxidative stress and tissue injury, have been correlated with patient severity, suggesting a molecular basis for their clinical stratification. Eighteen protein candidates were further validated by targeted proteomics in an independent cohort of 84 patients including a group of individuals that had satisfactorily resolved SARS-CoV-2 infection. Remarkably, all protein alterations were normalized 100 days after leaving the hospital, which further supports the reliability of the selected proteins as hallmarks of COVID-19 progression and grading. The optimized protein panel may prove its value for optimal severity assessment as well as in the follow up of COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The number of anti-inflammatory interventions in CHD-related studies has generally increased over the past 30 years. It shows that inflammation, as a critical pathological change during atherosclerosis progression, is attracting increasing attention from researchers ( 63 ). Early studies confirmed the correlation between CRP and inflammatory mechanisms in CHD.…”

Section: Discussionmentioning

confidence: 99%

Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022

Zhang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCoronary heart disease (CHD) is characterized by forming of arterial plaques composed mainly of lipids, calcium, and inflammatory cells. These plaques narrow the lumen of the coronary artery, leading to episodic or persistent angina. Atherosclerosis is not just a lipid deposition disease but an inflammatory process with a high-specificity cellular and molecular response. Anti-inflammatory treatment for CHD is a promising therapy; several recent clinical studies (CANTOS, COCOLT, and LoDoCo2) provide therapeutic directions. However, bibliometric analysis data on anti-inflammatory conditions in CHD are lacking. This study aims to provide a comprehensive visual perspective on the anti-inflammatory research in CHD and will contribute to further research.Materials and methodsAll the data were collected from the Web of Science Core Collection (WoSCC) database. We used the Web of Science’s systematic tool to analyze the year of countries/regions, organizations, publications, authors, and citations. CiteSpace and VOSviewer were used to construct visual bibliometric networks to reveal the current status and emerging hotspot trends for anti-inflammatory intervention in CHD.Results5,818 papers published from 1990 to 2022 were included. The number of publications has been on the rise since 2003. Libby Peter is the most prolific author in the field. “Circulation” was ranked first in the number of journals. The United States has contributed the most to the number of publications. The Harvard University System is the most published organization. The top 5 clusters of keywords co-occurrence are inflammation, C-reactive protein, coronary heart disease, nonsteroidal anti-inflammatory, and myocardial infarction. The top 5 literature citation topics are chronic inflammatory diseases, cardiovascular risk; systematic review, statin therapy; high-density lipoprotein. In the past 2 years, the strongest keyword reference burst is “Nlrp3 inflammasome,” and the strongest citation burst is “Ridker PM, 2017 (95.12).”ConclusionThis study analyzes the research hotspots, frontiers, and development trends of anti-inflammatory applications in CHD, which is of great significance for future studies.

show abstract

“…Additionally, circulating miRNA-933 has proven to be related with hyperlipidemia (AUC = 0.739) and atherosclerosis (AUC = 0.703) [ 41 ]. A circulating protein panel including IGHA2, APOA, and HPT was also identified to predict AS development (AUC = 0.73) [ 42 ]. Therefore, the cfDI (AUC = 0.780) identified in our study has a comparable diagnostic value as the above biomarkers for AS patients.…”

Section: Discussionmentioning

confidence: 99%

Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis

Qian

Lou

et al. 2022

Cells

View full text Add to dashboard Cite

Atherosclerosis (AS) is the leading cause of cardiovascular diseases (CVDs) with a high rate of mortality worldwide. Plasma cell-free DNA (cfDNA), mainly originating from apoptosis, necrosis, and active secretion, has been recognized as a promising biomarker for the diagnosis and prognosis of multiple cancers, whereas there are no reports about cfDNA in CVDs. Here, we found an increased quantity and decreased integrity of cfDNA (cfDI) in the serum from AS patients compared with normal controls. Moreover, the reduced cfDI is inversely correlated with serum LDL levels, carotid plaque size, and carotid plaque thickness in the progression of AS. Consistently, in vivo experiments confirmed that the release and cleavage of cfDNA were increased concomitantly with the development and progression of AS in ApoE−/− mice. Our study sheds light on the potential of cfDNA and cfDI as molecular biomarkers for detecting and monitoring AS.

show abstract

Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

Cited by 36 publications

References 53 publications

Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment

Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment

Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022

Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis

Contact Info

Product

Resources

About